Un istituto di riferimento dove la ricerca sui tumori diventa cura in tempo reale

Molecular imaging to identify specific oncological targets, such as prostate cancer, neuroendocrine tumors, or breast cancer is gaining attention. At present, the most promising   developments in clinical research are related to the prostate-specific membrane antigen (PSMA). PSMA represents an ideal target both for imaging and therapy, namely in the advanced stages of hormone-resistant prostate cancer as well as in early stages with hormone-sensitive disease.

New molecular targets have recently been identified to explore the tumor-microenviroment, especially towards cancer-associated fibroblasts (CAFs). In this scenario, radiopharmaceuticals for PET imaging (FAPi PET) have recently been developed. These new tracers consist of small peptide inhibitors targeting the fibroblast activation protein (FAP). Therefore, the study of the tumor micro-environment with molecular imaging, and any future developments as theranostic agents, represents one of the areas of greatest scientific interest in nuclear medicine.

Scientific Director: Francesco Ceci, Laura L. Travaini

Free Registration

Registration: https://ems.mzcongressi.com/start/1875/ita

More information: https://ems.mzcongressi.com/gestionale/documenti/evento/1875/brochure_ENG_pag_singole_132926772552060230.pdf